about
Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.Antimicrobial Stewardship in Australian Hospitals and Other Settings.Does Critical Illness Change Levofloxacin Pharmacokinetics?We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?Antimicrobial stewardship in Victorian hospitals: a statewide survey to identify current gaps.Antimicrobial stewardship of β-lactams in intensive care units.A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit.The use and risks of antibiotics in critically ill patients.Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?Should β-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists.Antibiotic dose optimization in critically ill patients.The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs.Measuring antimicrobial prescribing quality in Australian hospitals: development and evaluation of a national antimicrobial prescribing survey tool.Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.Using periodic point-prevalence surveys to assess appropriateness of antimicrobial prescribing in Australian private hospitals.Implementing antimicrobial stewardship in the Australian private hospital system: a qualitative studyPost-operative iatrogenic pneumothorax and associated mortality: lessons learntAntimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study
P50
Q31058057-E2E906DD-19D8-40EC-A603-A469C74E8633Q36059155-A356E995-467F-4AB1-B56D-27560E790BFDQ36644695-634ED200-F45B-44E8-9439-FEC42893B8CAQ36970989-F7A08263-AEB2-4615-83EE-E283C1843DE3Q38162982-95A9848E-D155-486A-8740-6BADD62828E6Q38198157-FB7E48EE-238F-48AD-990A-74B95041F3DCQ38679343-5A9E7A02-899F-45F8-A9BD-D992FF132F7FQ38767901-154C9CFF-CC7A-4577-9CEB-9456DDCCCFC7Q40047150-D79D01A5-D4FC-4295-88F7-E093483081AEQ40674564-0A1AB408-2B92-4C8A-BE31-7CB8C5C90323Q40976961-BD250EE7-9DC5-4EAF-9063-AE6574F5EBBFQ41110594-0417866E-F98E-4358-91A6-EBE9C79D5BEFQ41337176-AF2BC400-B54C-4158-9200-214077421A28Q41441642-6FAE0875-5C41-46DE-9D99-C3787CB029E7Q42234982-BAE52C02-7E86-4AB6-8653-D9A50F445984Q86448904-606EF745-103F-4527-95F8-89F15A671814Q86512855-3AF59F32-1E4D-44F5-91FC-717624CA82E2Q96231998-F716C0A9-E623-40DE-A21D-83BBC5CF8CA1
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2058-2314
@en
name
Menino O Cotta
@ast
Menino O Cotta
@en
Menino O Cotta
@es
Menino O Cotta
@nl
type
label
Menino O Cotta
@ast
Menino O Cotta
@en
Menino O Cotta
@es
Menino O Cotta
@nl
prefLabel
Menino O Cotta
@ast
Menino O Cotta
@en
Menino O Cotta
@es
Menino O Cotta
@nl
P106
P1153
56485412900
P31
P496
0000-0002-2058-2314